VITAMIN C MAY FIGHT CANCER — BUT NOT THE WAY SCIENTISTS ONCE THOUGHT

Recent research suggests that intravenous vitamin C may act as an experimental cancer drug, a possibility that contrasts with earlier studies using oral vitamin C pills that found no benefit. The new findings, reported by Health & Medicine News – Science, indicate that higher concentrations achieved through IV administration could damage cancer cells and reduce the side effects of standard treatments.

According to Health & Medicine News – Science, intravenous vitamin C reaches concentrations far greater than those attainable with supplements, allowing it to behave more like a drug than a nutritional agent. Early clinical observations show it may selectively harm vulnerable cancer cells, lessen treatment‑related side effects, and, for some patients, improve outcomes. These results revive the debate sparked by Linus Pauling’s controversial claims, which were previously mocked after trials with vitamin C tablets proved ineffective.

The work is part of a broader reevaluation of vitamin C’s role in oncology, following years of skepticism after earlier randomized trials failed to demonstrate benefit with oral dosing. It underscores how delivery method can dramatically alter a compound’s therapeutic potential.

• Intravenous vitamin C achieves much higher blood concentrations than oral supplements.
• Early studies show potential to damage cancer cells, reduce side‑effect burden, and improve outcomes for some patients.
• The findings revive interest in vitamin C as a cancer treatment, revisiting Linus Pauling’s long‑debated hypothesis.

Read the original source for full detail available at Health & Medicine News -- Scienc src